Novo Nordisk vs. Biocon: Liraglutide Patent Dispute Settled in Delaware
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Novo Nordisk A/S v. Biocon Pharma Ltd. |
| Case Number | 1:22-cv-00937 (D. Del.) |
| Court | U.S. District Court for the District of Delaware |
| Duration | Jul 2022 – Mar 2024 1 year 8 months |
| Outcome | Settlement — Confidential Terms |
| Patents at Issue | and 15 additional patents. |
| Accused Products | Biocon’s generic liraglutide solution injection (18 mg/3 mL, 6 mg/mL) |
Case Overview
The Parties
⚖️ Plaintiff
Danish pharmaceutical giant, global innovator behind liraglutide-based therapies, including Victoza® and Saxenda®.
🛡️ Defendant
India-headquartered biopharmaceutical company with an expanding U.S. generics and biosimilars strategy.
The Patents at Issue
This litigation involved **18 U.S. patents**, with the primary infringement allegations focused on formulation aspects, delivery device technology, and peptide chemistry, typical of layered pharmaceutical patent protection strategies.
- • US 8,920,383 — covering formulation aspects of liraglutide injectable solutions
- • US 9,265,893 — directed to drug delivery and administration technology
- • US 9,775,953 — covering peptide formulation and stability claims
Developing a GLP-1 therapy?
Check if your pharmaceutical formulation or device might infringe these or related patents.
The Verdict & Legal Analysis
Outcome
The case was **dismissed without prejudice** pursuant to a **Confidential Settlement and License Agreement** executed between Novo Nordisk and Biocon. All claims, counterclaims, and affirmative defenses concerning the patents at issue were dismissed. Each party bears its own attorneys’ fees and costs. No damages amount was disclosed, consistent with pharmaceutical ANDA settlement confidentiality norms.
Verdict Cause Analysis
The action was triggered by Biocon’s **Paragraph IV ANDA filing**, which constituted a statutory act of infringement under 35 U.S.C. § 271(e)(2). Biocon countered with validity and non-infringement defenses — the standard dual-track defense in ANDA litigation. Because the case resolved pre-trial, no judicial claim construction ruling, summary judgment ruling on validity or infringement, or trial record was generated.
Legal Significance
This case reinforces several doctrinal and strategic patterns in pharmaceutical patent litigation:
- **Portfolio depth as a deterrent**: Asserting 18 patents simultaneously creates substantial litigation risk for generic challengers, increasing settlement leverage regardless of individual patent strength.
- **Consolidation strategy**: By consolidating against multiple ANDA filers under a lead case, Novo Nordisk achieved discovery efficiencies while signaling coordinated enforcement.
- **Dismissal without prejudice**: This structure keeps patent rights intact, allowing Novo Nordisk to re-assert patents if Biocon breaches settlement terms or launches outside the agreed window.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in the GLP-1 receptor agonist space. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View all 18 related patents in the GLP-1 technology space
- See which companies are most active in biologics patents
- Understand formulation and device claim construction patterns
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own technology or product.
- Input your product description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
GLP-1 receptor agonist injectables
18 Related Patents
In GLP-1 and injectable biologics
Design-Around Options
Complex, but possible for some claims
✅ Key Takeaways
Multi-patent ANDA assertions (18 patents here) significantly increase settlement leverage even without reaching claim construction.
Search related case law →Dismissal without prejudice in ANDA settlements preserves enforcement options — critical if authorized entry terms are violated.
Explore precedents →Frequently Asked Questions
The case involved 18 U.S. patents protecting Saxenda® (liraglutide), with primary allegations focused on U.S. Patent Nos. 8,920,383; 9,265,893; and 9,775,953, covering formulation, delivery, and peptide chemistry claims.
The parties entered a Confidential Settlement and License Agreement, resulting in stipulated dismissal without prejudice. Biocon retained the right to maintain its Paragraph IV ANDA certifications and pursue FDA final approval.
It reinforces that generic challengers in the GLP-1 space will likely secure market access through negotiated authorized-entry licenses rather than litigation victories, given Novo Nordisk’s extensive and aggressively enforced patent portfolio.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- United States District Court for the District of Delaware — Case 1:22-cv-00937
- U.S. Patent and Trademark Office — Patent Center (for asserted patents)
- Cornell Legal Information Institute — 35 U.S.C. § 271(e)(2) (Hatch-Waxman Act)
- PatSnap — IP Intelligence for Pharmaceutical Companies
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.